

1. PRODUCT AND COMPANY INFORMATION

Distributed By: WG Critical Care, LLC.

120 Route 17 North

Suite 115

Paramus, NJ 07652 USA

Product Name: Ceftriaxone for Injection, USP

Product Code: 1g Vial: 44567-701-10

2g Vial 44567-702-10 10g Vial 44567-703-01

Common / Trade Name: Ceftriaxone for Injection, USP

Structure:

Chemical Name: (1) 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2-amino-4-

thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, disodium salt, [6R-[6a,7b(Z)]]-, hydrate (2:7); (2) (6R,7R)-7-[2-(2-Amino-4-thiazolyl)glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-

carboxylic acid, 7^2 -(Z)-(O-methyloxime), disodium salt, sesquaterhydrate

UNII Code: *UNII-023Z5BR09K* **CAS Number:** 104376-79-6

Chemical Family:AntibacterialProduct Use:PharmaceuticalProduct Type:Prescription Drug

Container Information: Vials

Ceftriaxone for Injection, USP		Material Safety Data Sheet (MSDS)	
Version: 1.2	Issue Date: 23 July 2012		Page 1 of 6



1. PRODUCT AND COMPANY INFORMATION (CONT.)

General Phone Number: +1-224-544-5632 Customer Service Phone Number: +1-888-493-0861

Emergency Phone Number: +1-866-562-4708 (Prosar)

2. COMPOSITION / INFORMATION ON INGREDIENTS

IngredientWeight %CAS No.Ceftriaxone Sodium100104376-79-6

3. HAZARDS INDENTIFICATION

PRIMARY PHYSICAL AND HEALTH May cause irritations to the skin and eyes. May cause allergic

HAZARDS: reactions.

ROUTES OF ENTRY: Skin. Inhalation, Ingestion. Eye.

SIGNS & SYMPTOMS OF EXPOSURE: Acute signs and symptoms of exposure may include eye, skin,

and respiratory irritation. May cause nausea, vomiting,

abdominal pain, headache, dizziness, light headedness, or skin

rash.

CHEMICAL LISTED AS CARCINOGEN: NTP: NO IARC: NO OSHA: NO

4. FIRST AID MEASURES

EYE EXPOSURE: Flush eyes with water for 10-20 minutes. Seek medical attention.

SKIN EXPOSURE: Remove contaminated clothing wash skin for 15-20 minutes with

soap and water. Seek medical attention.

INGESTION: Do NOT induce vomiting. Flush mouth with water and seek

medical attention immediately.

INHALATION: If there is breathing difficulty, remove from exposure and

administer oxygen. See medical attention immediately.

NOTE TO PHYSICIAN: See patient package insert in shipping carton for complete

information.

Ceftriaxone for Injection, USP		Material Safety Data Sheet (MSDS)	
Version: 1.2	Issue Date: 23 July 2012		Page 2 of 6



5. FIRE FIGHTING MEASURES

FLASH POINT: Not Established

AUTO-IGNITION TEMPERATURE: Not Established

FLAMMABLE LIMITS IN AIR: Not Established

FLAMMABLE LIMITS: Not Established

EXTINGUISHING MEDIA: Water Spray, carbon dioxide, dry powder. Do not use a heavy

stream of water.

UNUSUAL FIRE / EXPLOSION

HAZARDS:

When heated to decomposition material, it emits toxic fumes:

carbon monoxide, carbon dioxide, nitrogen oxides, sulfur

compounds.

6. ACCIDENTAL RELEASE MEASURE

SPILL: Contain and collect spillage and place in container for disposal

according to local regulations (See Section 13). Wipe surface area clean with soap and water. Avoid contact with strong oxidizing

agents.

RELEASE TO AIR: Prevent release to environment. If aerosolized reduce exposure by

ventilating area.

RELEASE TO WATER: Refer to local water authority. Drain disposal is not recommended;

refer to local, state, and federal disposal guidelines.

7. HANDLING AND STORAGE

GENERAL HANDLING: When handling pharmaceutical products, avoid all contact and

inhalation of dust, fumes, mist, and/or vapors associated with the

product. Keep away from sources of ignition.

STORAGE CONDITIONS: Keep containers tightly closed in a cool, well-ventilated place.

Store at room temperature between 20°C and 25°C (68°F and

77°F).

Ceftriaxone for Injection, USP		Material Safety Data Sheet (MSDS)	
Version: 1.2	Issue Date: 23 July 2012		Page 3 of 6



8. EXPOSURE CONTROLS / PERSONAL PROTECTION

RESPIRATORY PROTECTION: If aerosols are generated, a disposable dust/mist respirator

(N95) may be used. Personnel wearing respirators should be fit tested and approved for respirator use under the OSHA

Respiratory Protection Standard 29

CFR 1910.134.

EYE PROTECTION: Chemical goggles and/or face shield. Safety glasses are

always required.

VENTILATION: Laboratory fume hood or local exhaust ventilation.

SKIN PROTECTION: Work uniform or laboratory coat.

OTHER PROTECTIVE EQUIPMENT: Protective Latex or Nitrile gloves

ADDITIONAL EXPOSURE

PRECAUTIONS:

In production settings, airline-supplied, hood-type

respirators are preferred. Shower and change clothing if skin

contact occurs.

9. PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE: Solid SPECIFIC GRAVITY: Not Established

APPEARANCE AND ODOR: White to yellowish EVAPORATION RATE: Not established

orange / N.D.

BOILING POINT: Not established **MELTING POINT:** >155°C (decomposes)

VAPOR PRESSURE: Not established **SOLUBILITY IN WATER:** Freely soluble

VAPOR DENSITY: Not established **pH:** 6.0-8.0

Ceftriaxone for Injection, USP		Material Safety Data Sheet (MSDS)	
Version: 1.2	Issue Date: 23 July 2012		Page 4 of 6



10. STABILITY AND REACTIVITY

STABILITY: Keep containers tightly closed in a cool, well-ventilated place.

Store at room temperature between 20°C and 25°C (68°F and

77°F).

INCOMPATIBILITY:

Strong oxidizing agents

(MATERIALS TO AVOID)

HAZARDOUS POLYMERIZATION: Will not occur

HAZARDOUS DECOMPISITION: When heated to decomposition material, it emits toxic fumes:

carbon monoxide, carbon dioxide, nitrogen oxides, sulfur

compounds.

CONDITIONS TO AVOID: Avoid exposure to light, heat and strong oxidizing agents.

11. TOXICOLOGICAL INFORMATION

ACUTE TOXICITY

COMPONENT	TYPE	ROUTE	SPECIES	DOSAGE
Ceftriaxone Sodium	LD ₅₀	Oral	Mouse	> 10g/kg
Ceftriaxone Sodium	LD ₅₀	Oral	Rat	>10g/kg
Ceftriaxone Sodium	LD ₅₀	Intravenous	Mouse	2.8g/kg
Ceftriaxone Sodium	LD ₅₀	Intravenous	Rat	2g/kg
Ceftriaxone Sodium	LD ₅₀	Intravenous	Rabbit	240mg/kg

12. ECOLOGICAL INFORMATION

No applicable information found.

13. DISPOSAL CONSIDERATIONS

WASTE DISPOSAL: Waste disposal must be in accordance with appropriate Federal, State, and local regulations.

Ceftriaxone for Injection, USP		Material Safety Data Sheet (MSDS)	
Version: 1.2	Issue Date: 23 July 2012		Page 5 of 6



14. TRANSPORT INFORMATION

REGULATORY ORGANIZATIONS:

DOT: Not Regulated

ICAO / IATA: Not Regulated

IMO: Not Regulated

15. REGULATORY INFORMATION

Below is selected regulatory information chosen primarily for possible WG Critical Care use. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your city / state / country.

US Regulations

TSCA – No CERCLA-No SARA 302 – No SARA 313 – No OSHA Substance Specific - No

16. OTHER INFORMATION

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS MATERIAL SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PUROPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

\ \ / C	Critica	C 2 K 2	
ירועע	CHILICA	l Care,	LLU
•••	O c. ca	. - , -	

Ceftriaxone for Injection, USP		Material Safety Data Sheet (MSDS)	
Version: 1.2	Issue Date: 23 July 2012		Page 6 of 6